Researchers at the University of California, San Diego School of Medicine have erased and reactivated memories in rats, profoundly altering the animals’ reaction to past events. The study is the first to show the ability to selectively remove a memory and predictably reactivate it by stimulating nerves in the brain at frequencies that are known to weaken and strengthen the connections between nerve cells, called synapses.
Collaboration Combined with Revolutionary Technology opens new potential to identify new biomarkers and therapeutic points of intervention for use in the development of new Alzheimer’s treatments
Researchers have identified a protein recycling pathway in mammalian cells that removes misfolded proteins. They also demonstrated this pathway’s role in protecting against neurodegenerative diseases in an animal model.
Protea Biosciences Group, Inc. (OTCQB:PRGB) announced it has entered into a research collaboration with the University of Southampton, a leading biomedical and clinical research institution located in the United Kingdom. The collaboration will partner Protea’s proprietary direct molecular imaging technology and capabilities with a team of Alzheimer’s researchers at the University of Southampton, to study the molecular mechanisms of the aged brain, in order to identify markers that may indicate risk of developing Alzheimer’s disease.
People with high levels of cynical distrust may be more likely to develop dementia, according to a study published in the May 28, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology.
In March of this year, a team of Georgetown University scientists published research showing that, for the first time ever, a blood test has the potential to predict Alzheimer’s disease before patients start showing symptoms. AACC is pleased to announce that a late-breaking session at the 2014 AACC Annual Meeting & Clinical Lab Expo in Chicago will expand upon this groundbreaking research and discuss why it could be the key to curing this devastating illness.
The Lewy Body Dementia Association (LBDA) tells Americans DON’T FORGET to PAY IT FORWARD THIS MAY FOR MEMORY’S SAKE—with one click of the mouse anyone can help halt the rising tide of dementia. A small gift can make a big difference.
Scientists at The Scripps Research Institute have discovered that a protein with a propensity to form harmful aggregates in the body when produced in the liver protects against Alzheimer’s disease aggregates when it is produced in the brain.
Research in an animal model at Saint Louis University supports the potential therapeutic value of an antisense compound to treat Alzheimer's disease.
Casey Kasem’s heartbreaking diagnosis of Lewy body dementia is all over the news. The Associated Press reports Kasem, 82, had previously been incorrectly diagnosed as having an advanced form of Parkinson's disease. But what is Lewy body dementia and why might it misdiagnosed as Parkinson's or Alzheimer's disease?
A University of Pennsylvania researcher has discovered that the common selective serotonin reuptake inhibitor (SSRI) citalopram arrested the growth of amyloid beta, a peptide in the brain that clusters in plaques that are thought to trigger the development of Alzheimer’s disease (AD). Penn, in collaboration with investigators at Washington University, tested the drug’s effects on the brain interstitial fluid (ISF) in plaque-bearing mice and the cerebrospinal fluid (CSF) of healthy human subjects to draw its conclusions, which are detailed in the new issue of Science Translational Medicine.
A commonly prescribed antidepressant can reduce production of the main ingredient in Alzheimer’s brain plaques, according to new research at Washington University School of Medicine in St. Louis and the University of Pennsylvania.
Mutations in two presenilin proteins associated with familial Alzheimer's disease disrupt the flow of calcium ions within neurons. Researchers have found that suppressing the hyperactivity of the calcium channels alleviated FAD-like symptoms in mice models of the disease.
A new study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City has found that atrial fibrillation patients who are on blood thinning medications are at higher risk of developing dementia if their doses are not in the optimal recommended range.
A scientific team led by the Gladstone Institutes and UC San Francisco has discovered that a common form of a gene already associated with long life also improves learning and memory, a finding that could have implications for treating age-related diseases like Alzheimer’s.
In the first study of its kind, researchers have determined that spending time with horses eases symptoms of Alzheimer’s dementia.
Neuroscientists at Mayo Clinic in Florida have defined a subtype of Alzheimer’s disease (AD) that they say is neither well recognized nor treated appropriately.
Catch up on the latest in Alzheimer’s and Parkinson’s. Alzforum series delivers the highlights of new findings presented at a joint Keystone meeting.
With lifespans of up to 31 years, naked mole rats live decades longer than would be expected based on their size. A new study links their remarkable lifespans to high levels of a quality-control protein, offering new insights on age-related diseases like Alzheimer’s and Parkinson’s.
The stress hormone cortisol can negatively affect memory and learning ability in the elderly. Researchers at Loma Linda University found that showing a 20-minute funny video to healthy seniors and seniors with diabetes helped them score better on memory tests and significantly reduced their cortisol levels when compared to non-video watchers.
Mayo Clinic research studying the relationship between death and the two types of mild cognitive impairment (MCI) suggests that people who have these conditions die at a higher rate than people without MCI. The research was released today and will be presented at the American Academy of Neurology’s 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014.
Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer’s, Parkinson’s and Huntington’s diseases.
Today, if you hear, “Knock, knock,” on your cyber door, be sure to answer, “Who’s there?” You’ll hear Whoopi Goldberg say, “Lewy.“ To which you respond, of course, “Lewy who?” Glad you asked. The Lewy Body Dementia Association (LBDA) launched this month an awareness campaign – “Lewy Who?” – to educate the public about Lewy body dementia (LBD), the most misdiagnosed form of dementia and, following Alzheimer’s disease, the second most common cause of progressive dementia.
A new approach to handling agitation, aggression and other unwanted behaviors by people with dementia may help reduce the use of antipsychotics and other psychiatric drugs in this population, and make life easier for them and their caregivers.
A team of researchers from Columbia University Medical Center (CUMC), Weill Cornell Medical College, and Brandeis University has devised a wholly new approach to the treatment of Alzheimer's disease involving the so-called retromer protein complex. Retromer plays a vital role in neurons, steering amyloid precursor protein (APP) away from a region of the cell where APP is cleaved, creating the potentially toxic byproduct amyloid-beta, which is thought to contribute to the development of Alzheimer's.
Older people who have apathy but not depression may have smaller brain volumes than those without apathy, according to a new study published in the April 16, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. Apathy is a lack of interest or emotion.
Seniors living in the community who have dementia are more likely to be hospitalized and visit the emergency department than those who do not have dementia, according to a new study by researchers at RTI International.
A new study by researchers at Rush University Medical Center reviews research that suggests that the risk for developing Alzheimer’s disease among older African Americans may be two to three times greater than in the non-Hispanic white population and that they differ from the non-Hispanic white population in risk factors and disease manifestation. The study results will be published in the April 7 issue of Health Affairs.
More than 70% of elderly Medicare beneficiaries experience cognitive impairment or severe dementia near the end-of-life and may need surrogate decision makers for healthcare decisions. Advance care planning for older adults with dementia may be particularly important for individuals who do not reside in a nursing home or a long-term care facility, according to an article published in the April issue of Health Affairs.
How will we, as individuals, and a society, live with brains at risk for Alzheimer's disease dementia? As part of Health Affairs’ April issue, a theme issue focusing on Alzheimer’s, a neurodegenerative disease ethicist and clinician with the Perelman School of Medicine at the University of Pennsylvania offers keen observations to help navigate ethically-charged points on the course of the disease progression.
The Sanders-Brown Center on Aging recently published findings from a small cohort of participants suggesting a connection between the health of the brain tissue that supports cognitive functioning and the presence of dementia in adults with Down syndrome.
Young adults with such cardiac risk factors as high blood pressure and elevated glucose levels have significantly worse cognitive function in middle age, according to a new study by dementia researchers at UC San Francisco.
As part of an Alzheimer's disease prevention trial, Penn Medicine neurodegenerative ethics experts will monitor how learning about their risk of developing Alzheimer's impacts trial participants.
Investigators at the Cedars-Sinai Regenerative Medicine Institute have discovered eye abnormalities that may help reveal features of early-stage Alzheimer’s disease. Using a novel laboratory rat model of Alzheimer’s disease and high-resolution imaging techniques, researchers correlated variations of the eye structure, to identify initial indicators of the disease.
University of Michigan researchers have learned how to fix a cellular structure called the Golgi that mysteriously becomes fragmented in all Alzheimer's patients and appears to be a major cause of the disease.
A new pre-clinical study by researchers at Temple University found that people who experience chronic sleep disturbance could face an earlier onset of dementia and Alzheimer’s.
LBDA seeks to raise awareness of Lewy body dementia. The most misdiagnosed dementia, LBD affects 1.3 million Americans.
A team of scientists from the University of California, San Diego School of Medicine, the Medical University of South Carolina and San Diego-based American Life Science Pharmaceuticals, Inc., report that cathepsin B gene knockout or its reduction by an enzyme inhibitor blocks creation of key neurotoxic pGlu-Aβ peptides linked to Alzheimer’s disease. Moreover, the candidate inhibitor drug has been shown to be safe in humans.
Brain imaging using radioactive dye can detect early evidence of Alzheimer's disease that may predict future cognitive decline among adults with mild or no cognitive impairment, according to a 36-month follow-up study led by Duke Medicine.
It may now be possible to identify the first-stage Parkinson’s patients who will go on to develop dementia, according to a study conducted at the Institut universitaire de gériatrie de Montréal by Dr. Oury Monchi, PhD, and his postdoctoral student, Dr. Alexandru Hanganu, MD, PhD, both of whom are affiliated with Université de Montréal. These findings were published in the journal Brain.
Today, in recognition of Brain Awareness Week, from March 10 through March 16, 2014, the Lewy Body Dementia Association (LBDA) calls attention to critical differences in dementia-causing disorders that may have potentially life-saving implications.
Researchers at The Scripps Research Institute and Vanderbilt University have created the most detailed 3-D picture yet of a membrane protein linked to learning, memory, anxiety, pain and brain disorders such as schizophrenia, Parkinson’s, Alzheimer’s and autism.
A new study suggests that Alzheimer’s disease may contribute to close to as many deaths in the United States as heart disease or cancer. The research is published in the March 5, 2014, print issue of Neurology®, the medical journal of the American Academy of Neurology.
Three promising biomarkers being studied to detect Alzheimer’s disease in its early stages appear to undergo a surprising shift as patients develop symptoms of dementia, researchers at Washington University School of Medicine in St. Louis report.
Like mobsters following strict orders, newly engineered molecules called “ubiquibodies” can mark specific proteins inside a cell for destruction – a molecular kiss of death that is paving the way for new drug therapies and powerful research tools.
Scientists at The Scripps Research Institute have invented small-molecule folding probes that enable them to quantify functional, normally folded and disease-associated misfolded conformations (shapes) of a protein-of-interest in cells under different conditions.
Whitehead Institute scientists have used a yeast cell-based drug screen to identify a class of molecules that target the amyloid-β (Aβ) peptide involved in Alzheimer’s disease (AD).
Magtein™, a proprietary blend of magnesium –L-threonate, today released a “White Paper” demonstrating the extensive peer-reviewed and published science behind the product’s mechanism of action, its safety and efficacy. The product helps consumers maintain cognitive health, including slowing down but also reversing memory decline as well as addressing the serious health concerns of dementia and Alzheimer’s disease.
Results from an ongoing epidemiological study at the University of Kentucky Sanders-Brown Center on Aging suggests a connection between self-reported incidence of memory loss and cognitive memory impairment later in life.
Kidney cancer immunotherapy, MS and depression, ACE and Alzheimer's, air pollution and brain tumors, and more are story ideas detailed in the Feb. tipsheet from Cedars-Sinai.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right